Cargando…

Designer drugs 2015: assessment and management

Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Weaver, Michael F, Hopper, John A, Gunderson, Erik W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422150/
https://www.ncbi.nlm.nih.gov/pubmed/25928069
http://dx.doi.org/10.1186/s13722-015-0024-7
_version_ 1782370015629017088
author Weaver, Michael F
Hopper, John A
Gunderson, Erik W
author_facet Weaver, Michael F
Hopper, John A
Gunderson, Erik W
author_sort Weaver, Michael F
collection PubMed
description Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.
format Online
Article
Text
id pubmed-4422150
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44221502015-05-07 Designer drugs 2015: assessment and management Weaver, Michael F Hopper, John A Gunderson, Erik W Addict Sci Clin Pract Review Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment. BioMed Central 2015-03-25 2015 /pmc/articles/PMC4422150/ /pubmed/25928069 http://dx.doi.org/10.1186/s13722-015-0024-7 Text en © Weaver et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Weaver, Michael F
Hopper, John A
Gunderson, Erik W
Designer drugs 2015: assessment and management
title Designer drugs 2015: assessment and management
title_full Designer drugs 2015: assessment and management
title_fullStr Designer drugs 2015: assessment and management
title_full_unstemmed Designer drugs 2015: assessment and management
title_short Designer drugs 2015: assessment and management
title_sort designer drugs 2015: assessment and management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422150/
https://www.ncbi.nlm.nih.gov/pubmed/25928069
http://dx.doi.org/10.1186/s13722-015-0024-7
work_keys_str_mv AT weavermichaelf designerdrugs2015assessmentandmanagement
AT hopperjohna designerdrugs2015assessmentandmanagement
AT gundersonerikw designerdrugs2015assessmentandmanagement